Evidence map›Paper›PMID 38012591›Full record

ArticleBMC women's health2023

Evaluation of the applicability of internal controls on self-collected samples for high-risk human papillomavirus is needed.

Bo Verberckmoes, Tamara De Vos, Karel Maelegheer, Catherine Ali-Risasi, Yolande Sturtewagen, Marleen Praet, Davy Vanden Broeck, Elizaveta Padalko

Open access · goldAbstract read
In one paragraph

Article in BMC women's health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Evaluation ofDiagnostics (Basel, Switzerland) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Bo VerberckmoesDepartment of Public Health and Primary Care, Ghent University, International Centre for Reproductive Health (ICRH), Corneel Heymanslaan 10, Ghent, 9000, Belgium. bo.verberckmoes@ugent.be.
Tamara De VosDepartment of Diagnostic Sciences, Ghent University, Corneel Heymanslaan 10, Ghent, 9000, Belgium.
Karel MaelegheerAlgemeen Ziekenhuis Sint-Lucas Brugge, Sint-Lucaslaan 29, Brugge, 8310, Belgium.
Catherine Ali-RisasiDepartment of Clinical Biology, General Provincial Hospital of Kinshasa, Avenue Colonel Ebeya 169, Kinshasa, Democratic Republic of Congo.
Yolande SturtewagenDepartment of Diagnostic Sciences, Ghent University, Corneel Heymanslaan 10, Ghent, 9000, Belgium.
Marleen PraetDepartment of Diagnostic Sciences, Ghent University, Corneel Heymanslaan 10, Ghent, 9000, Belgium.
Davy Vanden BroeckDepartment of Public Health and Primary Care, Ghent University, International Centre for Reproductive Health (ICRH), Corneel Heymanslaan 10, Ghent, 9000, Belgium.
Elizaveta PadalkoDepartment of Diagnostic Sciences, Ghent University, Corneel Heymanslaan 10, Ghent, 9000, Belgium.
Ghent University · BEAZ Sint-Lucas · BEKinshasa General Hospital · CD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSelf-collection of cervical samples to detect high-risk human papillomavirus (hr-HPV) is a trending topic in primary cervical cancer screening. This study evaluates the applicability of a self-sampling device to routine molecular procedures for hr-HPV detection.

methodsIn a primary health care facility in Kinshasa, Congo, 187 self-collected samples (Evalyn Brush) were gathered and sent to Ghent University Hospital (UZ Ghent) and Algemeen Medisch Labo (AML) in Belgium where routine tests for hr-HPV were applied (Abbott RealTime hr-HPV and qPCR (E6/E7), respectively). Sample type effect was evaluated by comparing the internal control (IC) between the self-collected samples and routine, clinician-taken samples randomly selected from the UZ Ghent archive.

resultsIn UZ Ghent an error was encountered in 9.1% (17/187) of self-collected samples due to a lack of IC signal. The hr-HPV prevalence in the remaining 170 samples was 18,8%. Comparing IC results between the self-collected and clinician-collected groups, a significant difference (p < 0,001) was found, with higher IC signals in the clinician-collected group. In AML, an error was encountered in 17.6% (33/187) of samples, including 16/17 of the UZ Ghent. The remaining sample with IC error gave a negative result in AML. Among the 154 samples without IC error at AML, a correlation of 90% was seen between both laboratories with a 77% negativity rate.

conclusionTesting the self-collected specimens by 2 routine hr-HPV tests gave a high IC error rate (9.1-17.6%). A possible solution would be to differentiate cut-offs for IC values depending on sample type, as currently used cut-offs are set for clinician-taken samples.

Indexed as

Leukemia, Myeloid, AcutePapillomavirus InfectionsUterine Cervical NeoplasmsDemocratic Republic of the CongoEarly Detection of CancerFemaleHuman Papillomavirus VirusesHumansPapillomaviridaeSensitivity and SpecificitySpecimen HandlingHPV assayHuman papillomavirusInternal controlSelf-sampling

Identifiers

PMID38012591
PMCPMC10683318
OpenAlexW4389043213

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.